Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors
暂无分享,去创建一个
P. Meltzer | S. Steinberg | M. Roncalli | M. Tsokos | P. Zucali | A. Santoro | I. Petrini | H. S. Lee | G. Giaccone | J. Luo | K. Killian | Y. Wang | C. Lee
[1] A. Nicholson,et al. [The Masaoka-Koga stage classification for thymic malignancies clarification and definition of terms]. , 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[2] F. Bosetti,et al. The cyclooxygenase‐2 pathway via the PGE2 EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone‐induced demyelination , 2012, Journal of neurochemistry.
[3] V. Guallar,et al. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. , 2012, Biochemical pharmacology.
[4] R. Shaw,et al. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism , 2011, Nature Cell Biology.
[5] Anne-Marie C. Dingemans,et al. MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer , 2011, PloS one.
[6] G. Giaccone,et al. Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry , 2011, Oncogene.
[7] S. Gygi,et al. SCFFbw7 Regulates Cellular Apoptosis By Targeting Mcl-1 for Ubiquitination and Destruction , 2010, Nature.
[8] Yonghong Xiao,et al. SCFFBW 7 regulates cellular apoptosis by targeting MCL 1 for ubiquitylation and destruction , 2011 .
[9] G. Giaccone,et al. Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomas , 2010, Cancer.
[10] P. Meltzer,et al. Expression and Mutational Status of c-kit in Thymic Epithelial Tumors , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] B. Schäfer,et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. , 2010, The Journal of clinical investigation.
[12] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[13] Hai-rim Shin,et al. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. , 2009, Cancer genetics and cytogenetics.
[14] N. Girard,et al. Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas , 2009, Clinical Cancer Research.
[15] G. Wilding,et al. Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms. , 2009, Chest.
[16] A. Tangoku,et al. Aberrant methylation of tumour-related genes in thymic epithelial tumours. , 2009, Lung cancer.
[17] H. Dienemann,et al. Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma , 2008, International journal of cancer.
[18] C. Tse,et al. Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models , 2008, Clinical Cancer Research.
[19] G. Mazzini,et al. Multi-parametric flow cytometric cell cycle analysis using TO-PRO-3 iodide (TP3): detailed protocols. , 2008, Acta histochemica.
[20] Kotb Abdelmohsen,et al. p16INK4a Translation Suppressed by miR-24 , 2008, PloS one.
[21] W. Timens,et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. , 2008, European journal of cancer.
[22] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[23] Laurent Bélec,et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.
[24] G. Morgan,et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma , 2006, Leukemia.
[25] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[26] Elisabeth Brambilla,et al. Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .
[27] A. Marx,et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. , 2004, The New England journal of medicine.
[28] C. Pan,et al. Expression of apoptosis‐related markers and HER‐2/neu in thymic epithelial tumours , 2003, Histopathology.
[29] R. Penzel,et al. Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka , 2003, International journal of cancer.
[30] H. Müller-Hermelink,et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. , 2003, Cancer research.
[31] A. D’Andrea,et al. The Fanconi anaemia/BRCA pathway , 2003, Nature Reviews Cancer.
[32] Y. Haga,et al. Proliferative Activity and Apoptosis in Thymic Epithelial Neoplasms , 2002, Modern Pathology.
[33] P. Lazarovici,et al. Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. , 2001, Cancer research.
[34] A. Rosenwald,et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. , 2000, The American journal of pathology.
[35] S. Miyoshi,et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma , 1997, International journal of cancer.
[36] K. Stefanaki,et al. Expression of p53, mdm2, p21/waf1 and bcl‐2 proteins in thymomas , 1997, Histopathology.
[37] Y. Jin,et al. Immunohistochemical localization of Mcl‐1 and bcl‐2 proteins in thymic epithelial tumours , 1996, Histopathology.
[38] Å. Borg,et al. Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. , 1996, British Journal of Cancer.
[39] R. Schreiber,et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.